
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type based on the provided ranked marker list from a single-cell human dataset derived from breast cancer tissue, I will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **IL6 (Interleukin 6):** A cytokine involved in inflammation and the maturation of B cells. It plays a role in immune response and is often associated with inflammatory processes.<br>- **CSF3 (Colony Stimulating Factor 3):** Also known as G-CSF, it is involved in the production, differentiation, and function of granulocytes.<br>- **ANGPT2 (Angiopoietin 2):** Involved in angiogenesis and endothelial cell function.<br>- **SERPINE1 (PAI-1):** A serine protease inhibitor that plays a role in fibrinolysis and is involved in tissue remodeling and inflammation.<br>- **HMOX1 (Heme Oxygenase 1):** An enzyme that provides protection against oxidative stress.<br>- **CXCL8 (IL-8):** A chemokine involved in the recruitment of neutrophils and other immune cells to sites of inflammation.<br>- **CCL2 (MCP-1):** A chemokine that recruits monocytes, memory T cells, and dendritic cells to sites of tissue injury and infection.<br>- **CXCL2, CXCL3, CXCL1:** Chemokines involved in the recruitment of immune cells, particularly neutrophils.<br>- **NFKBIA (IŒ∫BŒ±):** An inhibitor of NF-Œ∫B, a key transcription factor in inflammatory responses.<br><br>### Step 2: List the Key Cell Type Markers<br>- **SELE (E-Selectin):** Expressed on endothelial cells activated by cytokines, involved in leukocyte adhesion and migration.<br>- **ECSCR (Endothelial Cell Specific Chemotaxis Regulator):** Specific to endothelial cells, involved in chemotaxis.<br>- **CD93:** A marker associated with endothelial cells and involved in cell adhesion and angiogenesis.<br>- **PLVAP (Plasmalemma Vesicle Associated Protein):** An endothelial cell marker involved in the formation of diaphragms in fenestrated endothelia.<br>- **ICAM1 (Intercellular Adhesion Molecule 1):** Expressed on endothelial cells and immune cells, involved in leukocyte endothelial transmigration.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Protein Atlas, PanglaoDB, and literature on scRNA-seq datasets, the markers listed are predominantly associated with endothelial cells, particularly those involved in angiogenesis, inflammation, and immune cell recruitment.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of markers such as SELE, ECSCR, CD93, PLVAP, and ICAM1, the most probable general cell type is **endothelial cells**. These markers are characteristic of endothelial cells, especially in the context of inflammation and angiogenesis, which are relevant in breast cancer tissue.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Inflammatory Endothelial Cells:** Given the high expression of inflammatory cytokines and chemokines (IL6, CXCL8, CCL2), these endothelial cells are likely involved in inflammatory responses.<br>2. **Angiogenic Endothelial Cells:** The presence of ANGPT2 and other angiogenesis-related markers suggests a role in new blood vessel formation.<br>3. **Activated Endothelial Cells:** The expression of adhesion molecules like SELE and ICAM1 indicates an activated state, often seen in response to cytokines in the tumor microenvironment.<br><br>**Most Likely Subtype:** Inflammatory Endothelial Cells, due to the prominent expression of inflammatory cytokines and chemokines.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset suggests that the cell cluster is most likely composed of endothelial cells. These cells are characterized by markers associated with inflammation, angiogenesis, and immune cell recruitment. The top probable subtypes are inflammatory endothelial cells, angiogenic endothelial cells, and activated endothelial cells, with inflammatory endothelial cells being the most likely subtype due to the high expression of inflammatory markers.<br><br>**FINAL ANNOTATION COMPLETED**
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The proposed annotation result is consistent with the provided marker list and the identified cell type. Here's the breakdown:<br><br>1. **Marker Consistency:**<br>   - The key functional markers and cell type markers listed in the annotation are present in the provided marker list. <br>   - The markers such as SELE, ECSCR, CD93, PLVAP, and ICAM1 are indeed associated with endothelial cells, supporting the annotation of the cell type as endothelial cells.<br>   - The presence of inflammatory markers like IL6, CXCL8, and CCL2 aligns with the identification of inflammatory endothelial cells as a probable subtype.<br><br>2. **Mixed Cell Type Consideration:**<br>   - The annotation considers the possibility of mixed subtypes within the endothelial cell category, such as inflammatory, angiogenic, and activated endothelial cells. This is appropriate given the expression of markers related to inflammation, angiogenesis, and activation.<br>   - There is no strong evidence of distinct, non-endothelial cell types based on the high-ranking markers provided, so the annotation does not need to be flagged for mixed cell types beyond the subtypes already considered.<br><br>Overall, the annotation is well-supported by the marker list and the context of breast cancer tissue, and the analysis appropriately identifies the most likely cell type and subtypes.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">Endothelial Cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Inflammatory Endothelial Cells</li><li>Angiogenic Endothelial Cells</li><li>Activated Endothelial Cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">85</div>
                        <div class="scoring-content">
                            The annotation results provided for the single-cell dataset derived from human breast cancer tissue are generally well-executed, with a few areas that could be improved. Here are the key points of evaluation:<br><br>1. **Correctness of Annotations:**<br>   - The identification of the main cell type as "Endothelial Cells" is scientifically accurate given the presence of markers such as SELE, ECSCR, CD93, PLVAP, and ICAM1, which are well-known markers for endothelial cells.<br>   - The subtypes identified (Inflammatory, Angiogenic, and Activated Endothelial Cells) are appropriate given the context of breast cancer tissue, where inflammation and angiogenesis are common processes.<br><br>2. **Balanced Consideration of Multiple Markers:**<br>   - The annotation process demonstrates a balanced consideration of multiple markers. The analysis does not overly focus on a single marker but rather integrates information from a range of markers, including those involved in inflammation (IL6, CXCL8, CCL2) and angiogenesis (ANGPT2).<br>   - The use of both functional and cell type-specific markers to determine the cell type and subtypes is a strength of the analysis.<br><br>3. **Ability to Capture the General Picture:**<br>   - The annotation captures the general picture of the cell populations present in the dataset. It considers the context of breast cancer tissue and the roles of endothelial cells in inflammation and angiogenesis.<br>   - The analysis appropriately identifies the most likely subtypes and provides a comprehensive view of the cell types present.<br><br>4. **Consideration of Marker Rank:**<br>   - While the annotation does consider a wide range of markers, it could have placed more emphasis on the rank of the markers. For instance, PCAT19, which appears first, is not discussed, and its relevance to the annotation is unclear. This could be a potential oversight.<br><br>5. **Potential Oversights:**<br>   - There is a lack of discussion on the significance of the first few markers in the list, such as PCAT19 and ADAMTS9, which could have provided additional insights or confirmed the annotation.<br>   - The annotation does not explore the possibility of other cell types that might be present, even if they are less likely, which could have provided a more nuanced view of the dataset.<br><br>Overall, the annotation is scientifically sound and provides a comprehensive view of the cell types present, with a balanced use of markers. However, it could benefit from a more detailed consideration of the rank of markers and potential exploration of other cell types.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    